News
ADLM 2024 – presentation of our new Micro-SCY service
From July 30th to August 1st, the Future Diagnostics team exhibited at ADLM โ24. We enjoyed connecting with our valued partners and new connections.
In addition, we presented a poster on our innovative micro-SCY technology for antibody-antigen interaction screening. Our poster was selected for an ๐๐ป๐ฑ๐๐๐๐ฟ๐ ๐๐ถ๐๐ถ๐๐ถ๐ผ๐ป’๐ ๐ฒ๐ฃ๐ผ๐๐๐ฒ๐ฟ ๐๐ถ๐๐ฐ๐๐๐๐ถ๐ผ๐ป (๐ผ๐ฟ๐ฎ๐น ๐ฝ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฎ๐๐ถ๐ผ๐ป).
Dutch grant โโMIT Haalbaarheidssubsidieโโ for further development of micro-SCYโข technology
Micro-SCYโข is an in-house developed, highly innovative method to screen antibody-antigen interactions in a biochemically relevant environment.
Future Diagnostics wishes you happy holidays
Our company is closed on Monday December 26th, 2022. Standard opening hours apply on all other days.
New Publication
Another critical step towards the clinical use of free 25OH Vitamin D measurement, as a marker for evaluating Vitamin D deficiency, has been recently published by Kerry Jones et al. Future Diagnostics is proud to be one of the authors who made this happen.
New Publication
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has once more emphasized the urgent need for accurate and fast point-of-care (POC) diagnostics for outbreak control and prevention. The main challenge in the development of POC in Vitro diagnostics (IVD)is to combine a short time to result with high sensitivity, and to keep the testing cost-effective. Future Diagnostics was happy to contribute to the realization of the publication.
Press release: Future Diagnostics celebrates 25th anniversary
On Friday, May 20, Future Diagnostics will celebrate its 25th anniversary. The company, which develops diagnostic tests on behalf of international biotech companies, will open its doors to invited guests that day. For a snack and a drink, the unveiling of its new logo and a tour of the laboratory in Wijchen.
Re-certification ISO13485:2016
Future Diagnostics proudly received the re-certification of ISO13485:2016 for the next 3 years. Zero non-conformities were found.
Development of Photonic Biosensor Device
Together with the BioCDx consortium, Future Diagnostics has been proudly working on the development of a miniaturized, reliable biosensing system for accurate and highly sensitive detection of protein cancer biomarkers, for the treatment monitoring of cancer disease and the therapeutics response.